CK Life Sciences Int'l. (Holdings) Past Earnings Performance
Past criteria checks 0/6
CK Life Sciences Int'l. (Holdings)'s earnings have been declining at an average annual rate of -22.4%, while the Biotechs industry saw earnings growing at 15.7% annually. Revenues have been growing at an average rate of 1.2% per year. CK Life Sciences Int'l. (Holdings)'s return on equity is 0.4%, and it has net margins of 0.3%.
Key information
-22.4%
Earnings growth rate
-22.4%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 1.2% |
| Return on equity | 0.4% |
| Net Margin | 0.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How CK Life Sciences Int'l. (Holdings) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 5,323 | 17 | 593 | 0 |
| 30 Sep 23 | 5,318 | 61 | 575 | 0 |
| 30 Jun 23 | 5,314 | 104 | 556 | 0 |
| 31 Mar 23 | 5,295 | 118 | 546 | 0 |
| 31 Dec 22 | 5,276 | 132 | 537 | 0 |
| 30 Sep 22 | 5,290 | 130 | 543 | 0 |
| 30 Jun 22 | 5,305 | 128 | 550 | 0 |
| 31 Mar 22 | 5,353 | 145 | 561 | 0 |
| 31 Dec 21 | 5,402 | 163 | 572 | 0 |
| 30 Sep 21 | 5,302 | 150 | 572 | 0 |
| 30 Jun 21 | 5,201 | 138 | 573 | 0 |
| 31 Mar 21 | 5,072 | 132 | 557 | 0 |
| 31 Dec 20 | 4,943 | 125 | 541 | 0 |
| 30 Sep 20 | 4,846 | 112 | 540 | 0 |
| 30 Jun 20 | 4,750 | 98 | 540 | 0 |
| 31 Mar 20 | 4,859 | 140 | 546 | 0 |
| 31 Dec 19 | 4,967 | 182 | 552 | 0 |
| 30 Sep 19 | 5,128 | 223 | 546 | 0 |
| 30 Jun 19 | 5,288 | 263 | 541 | 0 |
| 31 Mar 19 | 5,261 | 263 | 533 | 0 |
| 31 Dec 18 | 5,233 | 263 | 525 | 0 |
| 30 Sep 18 | 5,077 | 261 | 517 | 0 |
| 30 Jun 18 | 4,920 | 259 | 509 | 0 |
| 31 Mar 18 | 4,807 | 259 | 508 | 0 |
| 31 Dec 17 | 4,693 | 258 | 507 | 0 |
| 30 Sep 17 | 4,674 | 247 | 513 | 0 |
| 30 Jun 17 | 4,655 | 236 | 518 | 0 |
| 31 Mar 17 | 4,762 | 244 | 520 | 0 |
| 31 Dec 16 | 4,869 | 253 | 522 | 0 |
| 30 Sep 16 | 4,933 | 240 | 516 | 0 |
| 30 Jun 16 | 4,998 | 228 | 510 | 0 |
| 31 Mar 16 | 4,959 | 223 | 501 | 0 |
| 31 Dec 15 | 4,919 | 219 | 492 | 0 |
| 30 Sep 15 | 4,953 | 257 | 495 | 0 |
| 30 Jun 15 | 4,987 | 296 | 498 | 0 |
| 31 Mar 15 | 4,970 | 280 | 498 | 0 |
| 31 Dec 14 | 4,954 | 264 | 498 | 0 |
| 30 Sep 14 | 4,930 | 250 | 495 | 0 |
| 30 Jun 14 | 4,907 | 236 | 491 | 0 |
| 31 Mar 14 | 4,939 | 232 | 491 | 0 |
| 31 Dec 13 | 4,971 | 229 | 490 | 0 |
| 30 Sep 13 | 4,851 | 215 | 480 | 0 |
| 30 Jun 13 | 4,730 | 201 | 470 | 0 |
Quality Earnings: LSI has a large one-off gain of HK$133.6M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: LSI's current net profit margins (0.3%) are lower than last year (2.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LSI's earnings have declined by 22.4% per year over the past 5 years.
Accelerating Growth: LSI's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: LSI had negative earnings growth (-86.9%) over the past year, making it difficult to compare to the Biotechs industry average (-2.3%).
Return on Equity
High ROE: LSI's Return on Equity (0.4%) is considered low.